Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.
In the company’s own words · 10-K filed Mar 3, 2026 · SEC EDGAR
Business segments
Q1 2026 · $216.2MThe company’s own SEC segment disclosure.
- Molecular Profiling Services$210.8M98%
- Pharma Research And Development Services$5.4M2%
Caris Life Sciences, Inc. (CAI) reported revenue of $264M in Q2 2026 (quarter ended June 30, 2026), up 45% from the same quarter a year earlier. That came with net loss of $637K. For the full year FY2025, revenue was $812M (+97% year on year) and net income −$68M. Its largest product in 2026-Q1 was Molecular Profiling Services at $211M, 98% of the disclosed total, just ahead of Pharma Research And Development Services at 2.5%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.